Cargando…

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yungchang, Sun, Hao, Deng, Yanhong, Ma, Yutong, Huang, He, Liu, Yang, Zhang, Yaru, Zhang, Hongyu, Ye, Sheng, E, Mingyan, Guo, Hongqiang, Wu, Mengmeng, Wu, Chunman, Pu, Xingxiang, Chen, Xinggui, Liang, Chaoyong, Ou, Qiuxiang, Weng, Huawei, Wu, Xue, Shao, Yang, Gu, Anxin, Lin, Tongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875443/
https://www.ncbi.nlm.nih.gov/pubmed/36694231
http://dx.doi.org/10.1186/s40364-022-00443-8
_version_ 1784877962014752768
author Chen, Yungchang
Sun, Hao
Deng, Yanhong
Ma, Yutong
Huang, He
Liu, Yang
Zhang, Yaru
Zhang, Hongyu
Ye, Sheng
E, Mingyan
Guo, Hongqiang
Wu, Mengmeng
Wu, Chunman
Pu, Xingxiang
Chen, Xinggui
Liang, Chaoyong
Ou, Qiuxiang
Weng, Huawei
Wu, Xue
Shao, Yang
Gu, Anxin
Lin, Tongyu
author_facet Chen, Yungchang
Sun, Hao
Deng, Yanhong
Ma, Yutong
Huang, He
Liu, Yang
Zhang, Yaru
Zhang, Hongyu
Ye, Sheng
E, Mingyan
Guo, Hongqiang
Wu, Mengmeng
Wu, Chunman
Pu, Xingxiang
Chen, Xinggui
Liang, Chaoyong
Ou, Qiuxiang
Weng, Huawei
Wu, Xue
Shao, Yang
Gu, Anxin
Lin, Tongyu
author_sort Chen, Yungchang
collection PubMed
description BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups.  SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00443-8.
format Online
Article
Text
id pubmed-9875443
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98754432023-01-26 The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses Chen, Yungchang Sun, Hao Deng, Yanhong Ma, Yutong Huang, He Liu, Yang Zhang, Yaru Zhang, Hongyu Ye, Sheng E, Mingyan Guo, Hongqiang Wu, Mengmeng Wu, Chunman Pu, Xingxiang Chen, Xinggui Liang, Chaoyong Ou, Qiuxiang Weng, Huawei Wu, Xue Shao, Yang Gu, Anxin Lin, Tongyu Biomark Res Correspondence BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups.  SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00443-8. BioMed Central 2023-01-25 /pmc/articles/PMC9875443/ /pubmed/36694231 http://dx.doi.org/10.1186/s40364-022-00443-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Chen, Yungchang
Sun, Hao
Deng, Yanhong
Ma, Yutong
Huang, He
Liu, Yang
Zhang, Yaru
Zhang, Hongyu
Ye, Sheng
E, Mingyan
Guo, Hongqiang
Wu, Mengmeng
Wu, Chunman
Pu, Xingxiang
Chen, Xinggui
Liang, Chaoyong
Ou, Qiuxiang
Weng, Huawei
Wu, Xue
Shao, Yang
Gu, Anxin
Lin, Tongyu
The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title_full The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title_fullStr The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title_full_unstemmed The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title_short The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
title_sort clinical and genomic distinctions of class1/2/3 braf-mutant colorectal cancer and differential prognoses
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875443/
https://www.ncbi.nlm.nih.gov/pubmed/36694231
http://dx.doi.org/10.1186/s40364-022-00443-8
work_keys_str_mv AT chenyungchang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT sunhao theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT dengyanhong theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT mayutong theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT huanghe theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT liuyang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT zhangyaru theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT zhanghongyu theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT yesheng theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT emingyan theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT guohongqiang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wumengmeng theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wuchunman theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT puxingxiang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT chenxinggui theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT liangchaoyong theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT ouqiuxiang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wenghuawei theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wuxue theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT shaoyang theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT guanxin theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT lintongyu theclinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT chenyungchang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT sunhao clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT dengyanhong clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT mayutong clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT huanghe clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT liuyang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT zhangyaru clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT zhanghongyu clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT yesheng clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT emingyan clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT guohongqiang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wumengmeng clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wuchunman clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT puxingxiang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT chenxinggui clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT liangchaoyong clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT ouqiuxiang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wenghuawei clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT wuxue clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT shaoyang clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT guanxin clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses
AT lintongyu clinicalandgenomicdistinctionsofclass123brafmutantcolorectalcanceranddifferentialprognoses